Product Description
AMTX-100, a first-in-class and best-in-class peptide therapeutic, uses a novel untapped intracellular target (importins) to modulate inflammation using to improve the lives of patients with immune-mediated diseases. AMTX-100 is bioengineered from human protein sequences that modulate the immune system by a selective, natural process already used by cells, reducing pathogenesis in a range of conditions. AMTX-100 can bind to and penetrate immune cells to attenuate their intracellular molecular machinery and help ease inflammation early in the process in advance of gene activation. (Sourced from: https://www.amytrx.com/)
Mechanisms of Action: Inflammation Cascade Blocker
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amytrx Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic
Phase 1: Inflammation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12622000289718p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Inflammation |
2022-07-01 |
|||
NCT04313400 |
AMTX100-AD-01 | P2 |
Completed |
Dermatitis, Atopic |
2023-12-19 |
50% |
2024-01-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |